CareDx Net Income 2013-2024 | CDNA
CareDx net income from 2013 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
| CareDx Annual Net Income (Millions of US $) |
|
|---|---|
| 2024 | $53 |
| 2023 | $-190 |
| 2022 | $-77 |
| 2021 | $-31 |
| 2020 | $-19 |
| 2019 | $-22 |
| 2018 | $-47 |
| 2017 | $-55 |
| 2016 | $-39 |
| 2015 | $-14 |
| 2014 | $1 |
| 2013 | $-4 |
| 2012 | $-5 |
| CareDx Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2024-12-31 | $78 |
| 2024-09-30 | $-7 |
| 2024-06-30 | $-1 |
| 2024-03-31 | $-17 |
| 2023-12-31 | $-118 |
| 2023-09-30 | $-23 |
| 2023-06-30 | $-25 |
| 2023-03-31 | $-24 |
| 2022-12-31 | $-18 |
| 2022-09-30 | $-17 |
| 2022-06-30 | $-22 |
| 2022-03-31 | $-20 |
| 2021-12-31 | $-16 |
| 2021-09-30 | $-12 |
| 2021-06-30 | $-2 |
| 2021-03-31 | $-1 |
| 2020-12-31 | $-4 |
| 2020-09-30 | $-3 |
| 2020-06-30 | $-7 |
| 2020-03-31 | $-6 |
| 2019-12-31 | $-5 |
| 2019-09-30 | $-2 |
| 2019-06-30 | $-8 |
| 2019-03-31 | $-8 |
| 2018-12-31 | $-4 |
| 2018-09-30 | $-20 |
| 2018-06-30 | $-14 |
| 2018-03-31 | $-9 |
| 2017-12-31 | $-32 |
| 2017-09-30 | $-14 |
| 2017-06-30 | $-4 |
| 2017-03-31 | $-6 |
| 2016-12-31 | $-15 |
| 2016-09-30 | $-4 |
| 2016-06-30 | $-10 |
| 2016-03-31 | $-10 |
| 2015-12-31 | $-5 |
| 2015-09-30 | $-3 |
| 2015-06-30 | $-3 |
| 2015-03-31 | $-2 |
| 2014-12-31 | $0 |
| 2014-09-30 | $1 |
| 2014-06-30 | $1 |
| 2014-03-31 | $-1 |
| 2013-12-31 | $-1 |
| 2013-09-30 | $-1 |
| 2013-06-30 | $-1 |
| 2013-03-31 | $-1 |
| 2012-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.977B | $0.334B |
| CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $133.529B | 24.94 |
| Elevance Health (ELV) | United States | $96.108B | 12.88 |
| CVS Health (CVS) | United States | $84.839B | 12.41 |
| Cencora (COR) | United States | $55.604B | 20.18 |
| DiDi Global (DIDIY) | China | $20.317B | 29.86 |
| Natera (NTRA) | United States | $20.018B | 0.00 |
| BioMerieux (BMXMF) | France | $15.594B | 0.00 |
| Solventum (SOLV) | United States | $11.463B | 10.69 |
| ICON (ICLR) | Ireland | $11.251B | 10.22 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $11.063B | 0.00 |
| Revvity (RVTY) | United States | $11.032B | 18.74 |
| CochLear (CHEOY) | Australia | $10.876B | 0.00 |
| Avantor (AVTR) | United States | $10.289B | 15.10 |
| Doximity (DOCS) | United States | $9.934B | 51.66 |
| Viatris (VTRS) | United States | $9.024B | 2.85 |
| Medpace Holdings (MEDP) | United States | $8.956B | 23.46 |
| Sonic Healthcare (SKHHY) | Australia | $7.706B | 0.00 |
| HealthEquity (HQY) | United States | $7.311B | 35.97 |
| Charles River Laboratories (CRL) | United States | $5.209B | 10.28 |
| Amplifon S.p.A (AMFPF) | Italy | $4.285B | 22.62 |
| Bausch + Lomb (BLCO) | Canada | $4.262B | 19.45 |
| Alignment Healthcare (ALHC) | United States | $3.499B | 0.00 |
| Sotera Health (SHC) | United States | $2.975B | 17.18 |
| BrightSpring Health Services (BTSG) | United States | $2.905B | 30.18 |
| Organon (OGN) | United States | $2.868B | 2.92 |
| Surgery Partners (SGRY) | United States | $2.708B | 31.21 |
| GeneDx Holdings (WGS) | United States | $2.680B | 318.23 |
| Concentras Parent (CON) | United States | $2.613B | 13.59 |
| Progyny (PGNY) | United States | $1.837B | 40.45 |
| Ardent Health Partners (ARDT) | United States | $1.786B | 0.00 |
| Premier (PINC) | United States | $1.765B | 11.30 |
| GoodRx Holdings (GDRX) | United States | $1.720B | 37.38 |
| Agilon Health (AGL) | United States | $1.649B | 0.00 |
| PACS (PACS) | United States | $1.411B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.197B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.100B | 9.22 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.035B | 0.00 |
| Establishment Labs Holdings (ESTA) | $0.907B | 0.00 | |
| Nutex Health (NUTX) | United States | $0.824B | 16.14 |
| AMN Healthcare Services Inc (AMN) | United States | $0.706B | 5.59 |
| Embecta (EMBC) | United States | $0.659B | 4.52 |
| Auna S.A (AUNA) | Luxembourg | $0.515B | 13.65 |
| QDM (QDMI) | Hong Kong, SAR China | $0.496B | 0.00 |
| SBC Medicals (SBC) | United States | $0.417B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.405B | 0.00 |
| Enhabit (EHAB) | United States | $0.388B | 36.57 |
| InnovAge Holding (INNV) | United States | $0.372B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.290B | 0.00 |
| LifeMD (LFMD) | United States | $0.242B | 0.00 |
| DocGo (DCGO) | United States | $0.216B | 8.83 |
| Performant Healthcare (PHLT) | United States | $0.195B | 0.00 |
| Oncology Institute (TOI) | United States | $0.163B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.128B | 0.00 |
| Beauty Health (SKIN) | United States | $0.106B | 0.00 |
| So-Young (SY) | China | $0.084B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.082B | 0.00 |
| OncoCyte (OCX) | United States | $0.081B | 0.00 |
| Biodesix (BDSX) | United States | $0.080B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.065B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.062B | 0.00 |
| NeueHealth (NEUE) | United States | $0.053B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.027B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.018B | 0.00 |
| ModivCare (MODV) | United States | $0.014B | 4.93 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.011B | 0.00 |
| KindlyMD (KDLY) | United States | $0.011B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| Aclarion (ACON) | United States | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |